USA - New York Stock Exchange - NYSE:A - US00846U1016 - Common Stock
The current stock price of A is 154.37 USD. In the past month the price increased by 7.8%. In the past year, price increased by 11.89%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 26.48 | 224.02B | ||
| DHR | DANAHER CORP | 29.63 | 163.59B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 189.06 | 57.37B | ||
| IQV | IQVIA HOLDINGS INC | 19.93 | 39.41B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 35.53 | 30.62B | ||
| WAT | WATERS CORP | 32.06 | 24.23B | ||
| ILMN | ILLUMINA INC | 29.77 | 19.95B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 39.2 | 19.93B | ||
| MEDP | MEDPACE HOLDINGS INC | 42.42 | 17.09B | ||
| TEM | TEMPUS AI INC | N/A | 13.41B | ||
| RVTY | REVVITY INC | 21.85 | 12.15B | ||
| TECH | BIO-TECHNE CORP | 33.49 | 10.07B |
Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. The company is headquartered in Santa Clara, California and currently employs 18,000 full-time employees. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Life Sciences and Diagnostics Markets segment comprises seven areas of activity. The company offers active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. Agilent CrossLab segment offers a services and consumables portfolio that spans the entire lab, in addition to software and laboratory automation solutions, which are designed to enhance customer outcomes. Applied Markets segment offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products.
AGILENT TECHNOLOGIES INC
5301 Stevens Creek Blvd
Santa Clara CALIFORNIA 95051 US
CEO: Michael R. McMullen
Employees: 18000
Phone: 14083458886
Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. The company is headquartered in Santa Clara, California and currently employs 18,000 full-time employees. Its segments include Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets. Life Sciences and Diagnostics Markets segment comprises seven areas of activity. The company offers active pharmaceutical ingredients for oligo-based therapeutics as well as solutions that include reagents, instruments, software and consumables. Agilent CrossLab segment offers a services and consumables portfolio that spans the entire lab, in addition to software and laboratory automation solutions, which are designed to enhance customer outcomes. Applied Markets segment offers application-focused solutions that include instruments and software that enable customers to identify, quantify and analyze the physical and biological properties of substances and products.
The current stock price of A is 154.37 USD. The price decreased by -1.8% in the last trading session.
AGILENT TECHNOLOGIES INC (A) has a dividend yield of 0.66%. The yearly dividend amount is currently 0.95.
A has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
A stock is listed on the New York Stock Exchange exchange.
27 analysts have analysed A and the average price target is 154.27 USD. This implies a price decrease of -0.07% is expected in the next year compared to the current price of 154.37.
The PE ratio for AGILENT TECHNOLOGIES INC (A) is 27.66. This is based on the reported non-GAAP earnings per share of 5.58 and the current share price of 154.37 USD.
ChartMill assigns a technical rating of 9 / 10 to A. When comparing the yearly performance of all stocks, A is one of the better performing stocks in the market, outperforming 83.6% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to A. While A belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health.
Over the last trailing twelve months A reported a non-GAAP Earnings per Share(EPS) of 5.58. The EPS increased by 5.48% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 17.97% | ||
| ROA | 9.98% | ||
| ROE | 19.15% | ||
| Debt/Equity | 0.54 |
27 analysts have analysed A and the average price target is 154.27 USD. This implies a price decrease of -0.07% is expected in the next year compared to the current price of 154.37.
For the next year, analysts expect an EPS growth of 10.01% and a revenue growth 5.51% for A